Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands
about
Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccineSalmonella Typhi Porins OmpC and OmpF Are Potent Adjuvants for T-Dependent and T-Independent Antigens.Antitumor Activity of Portulaca Oleracea L. Polysaccharide on HeLa Cells Through Inducing TLR4/NF-κB Signaling.Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses.Characterization of Innate Responses Induced by PLGA Encapsulated- and Soluble TLR Ligands In Vitro and In Vivo in Chickens.Immune adjuvant effect of a Toxoplasma gondii profilin-like protein in autologous whole-tumor-cell vaccination in mice.The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy.Immune balance in Hepatitis B Infection: Present and Future Therapies.Advances in Antiviral Therapies Targeting Toll-like Receptors.Immunological effects of a novel RNA-based adjuvant in liver cancer patients.Development of Peptide Vaccines in Dengue.Therapeutic effect of monophosphoryl lipid A administration on Paracoccidioides brasiliensis-infected mice.Development of the CpG Adjuvant 1018: A Case Study.Association of Polymorphisms in Toll-Like Receptors 4 and 9 with Autoimmune Thyroid Disease in Korean Pediatric Patients.Fatty Acid-Mimetic Micelles for Dual Delivery of Antigens and Imidazoquinoline Adjuvants.A Fusion Protein Consisting of the Vaccine Adjuvant Monophosphoryl Lipid A and the Allergen Ovalbumin Boosts Allergen-Specific Th1, Th2, and Th17 Responses In Vitro.Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction.Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.Targeting of Immune Cells by Dual TLR2/7 Ligands Suppresses Features of Allergic Th2 Immune Responses in Mice.TLR8 combined withTLR3 or TLR4 agonists enhances DC-NK driven effector Tc1 cells.Humoral and cellular immune response induced by antigenic protein of Sarcoptes scabiei var. caprae.
P2860
Q30400146-461C176D-2D4B-47A7-9D41-4F8965A9C9CCQ30400261-EB1F5156-D409-4DC5-9CC6-EB3045021DC0Q32184375-BE6E332B-8750-4D3E-98FF-2F7632355623Q33746872-D07C2740-CA32-405E-9F20-3792A63A671EQ36238084-6B9259FE-5AA1-45B4-BC03-030CEED893E6Q37687530-64F5F5EE-75C8-42DD-B256-CF2ACE1A33ACQ37729321-5343E369-5D86-4AC2-960B-7EC7D010C021Q38733622-E6B85E71-F298-4770-B34B-DCD7E18E719CQ38733975-9D3E2363-E89A-48A9-83E8-C9E9FCE3DA3DQ39198568-83AADD74-761F-4A38-8FFC-D65BD107C851Q40038715-0BF80DD2-1326-4219-84E5-6DD0569FF4ECQ40537024-7EB96B94-6DC7-4A27-944B-55D3DB92A0D0Q40549653-1F863A21-E820-43A3-BDC7-B33F4D09C98BQ41622992-E4AAE22A-4245-42B3-AF53-080609C7353DQ42378276-1A58266C-23C5-4F99-BE94-C2BB42BEE9C4Q42713288-CE6873B7-C003-4790-9BD2-6996D3E8B1DAQ45074067-51403283-B7FE-4F43-B402-F77B5A136AD1Q47156322-1AF786AB-3DBC-4AF5-AA19-02185443CE64Q47159679-5458ACAE-F814-40C3-9099-97C89F90DCDEQ47656395-203A3572-69ED-4D06-AB88-2400FC3B71B0Q55714474-BD42B43C-EE12-426A-A040-3F66DE2D4D61
P2860
Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands
@ast
Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands
@en
type
label
Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands
@ast
Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands
@en
prefLabel
Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands
@ast
Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands
@en
P2860
P3181
P356
P1433
P1476
Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands
@en
P2093
Deana N Toussi
P2860
P304
P3181
P356
10.3390/VACCINES2020323
P577
2014-04-25T00:00:00Z